Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.

Zejula (niraparib) - GSK, J&J

OvaRex (oregovomab) - CanariaBio

Linda R. Duska; Angeles Alvarez Secord; Debra L. Richardson; Srinivas Rao Jada; Sunil Gupta

Apr 25, 2024